Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

The case for approving DBV’s peanut allergy vaccine; Celgene, Trump, and serial drug price hikes

  • Adam Feuerstein

By Adam Feuerstein Oct. 23, 2017

Reprints

Over the weekend, I asked my Twitter followers to weigh in on DBV Technologies’ (DBVT) chance of winning FDA approval for its experimental peanut allergy patch, given the failed phase 3 clinical trial reported Friday night.

The results, based on 900 responders:

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

New guidelines on severe brain injury complicate already difficult…
New guidelines on severe brain injury complicate already difficult decisions
Drug used to halt puberty in children may cause…
Drug used to halt puberty in children may cause lasting health problems
Muhammad Ali and Parkinson’s disease: Was boxing to blame?
Muhammad Ali and Parkinson’s disease: Was boxing to blame?
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…
J&J loses a patent battle in India over a…
J&J loses a patent battle in India over a crucial tuberculosis drug

Recommended Stories